L26/P-765 Serum biomarkers for diagnosis of adolescent polycystic ovary syndrome: a systematic review and meta-analysis
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1092 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von Y. Shi und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Study question What are the serum biomarkers for diagnosis and management of adolescent polycystic ovary syndrome (APCOS)? Summary answer Serum FAI, LH/FSH ratio, and AMH are effective serum biomarkers for APCOS diagnosis. What is known already Adolescent polycystic ovary syndrome (APCOS) is a common gynecological endocrinopathy posing lifelong risks to women’s health. However, the clinical phenotypes of APCOS often overlap with physiological pubertal adaptation, obscuring the diagnosis of APCOS and timely management. Blood-based biomarkers facilitate capturing the molecular signals for APCOS discrimination. Though existing studies have measured serum reproductive hormone levels and insulin resistance (IR) indices in adolescents with PCOS and healthy teenagers, their effect size and diagnostic performance in APCOS remain unclear. Study design, size, duration A systematic search was conducted across PubMed, Embase, Web of Science, Cochrane Library, Scopus, and Science Direct from their inception to June 2025. Methodological quality was assessed using 11-item checklist recommended by Agency for Healthcare Research and Quality (AHRQ) for cross-sectional studies, and evidence credibility was evaluated by Grading of Recommendations, Assessment, Development, and Evaluations frameworks (GRADE). The protocol was registered in PROSPERO (No. CRD420251033057). Participants/materials, setting, methods In the included studies, APCOS was diagnosed according to National Institutes of Health (NIH) criteria, 2003 Rotterdam criteria, Sultan and Paris’s criteria, or Androgen Excess and PCOS Society criteria, while the healthy control group included adolescents without features of PCOS under the same criteria as the corresponding APCOS group. The effect size, optimal cutoff value, and area under the receiver operating characteristic curve (AUC) of serum reproductive hormones and IR indices in APCOS were evaluated. Main results and the role of chance The meta-analysis included 52 studies in medium to high quality, synthesized data from 4767 adolescents aged 12-22 years old. Among the clinical parameters, ratio of luteinizing hormone to follicle-stimulating hormone (LH/FSH) (Hedges’ g = 1.31 (95% CI: 1.05-1.57), I2 = 42%) and homeostatic model assessment of insulin resistance (HOMA-IR) (Hedges’ g = 1.44 (95% CI: 1.02-1.86, I2 = 73%) exhibited a large overall effect size. Notably, free androgen index (FAI) presented significantly large effect size in non-obese group (Hedge’s g = 2.09 (95% CI = 1.35-2.75), I2 = 81%), while Anti-Müllerian hormone (AMH) exhibited a considerably large effect size in the obese group (Hedge’s g = 5.15 (95% CI = 1.47-8.82), I2 = 34%). For APCOS diagnosis, FAI and LH/FSH achieved comparable AUC of 0.77 (95% CI: 0.75-0.79) with thresholds of 5.56 and 1.61 in overall populations, respectively. Importantly, AMH achieved an AUC of 0.93 in the obese group (95% CI: 0.91-0.95, cutoff = 7.75 ng/mL). Limitations, reasons for caution The study is limited by inconsistency of diagnostic criteria, posing potential selection bias. Moreover, data were pooled from subjects spanning wide age range, which may cause age-specific effects due to substantial hormonal and metabolic fluctuations. More large and ethnically diverse cohorts are necessary to validify generalizability of the results. Wider implications of the findings Complementary to the 2025 international recommendations of APCOS, our data suggest that FAI and LH/FSH ratio are BMI-independent APCOS biomarkers, whereas AMH is discriminative in the obese group. Importantly, adolescent-specific cutoff values of the above reproductive hormones should be applied for precise APCOS diagnosis. Trial registration number Yes
Zitieren
APA
Shi, Y., Wang, C., Victorin, E., & Wang, Y. (2026). L26/P-765 Serum biomarkers for diagnosis of adolescent polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1092
Vancouver
Shi Y, Wang C, Victorin E, Wang Y. L26/P-765 Serum biomarkers for diagnosis of adolescent polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1092
BibTeX
@article{Shi2026,
author = {Shi, Y. and Wang, C.C. and Victorin, E.S. and Wang, Y.},
title = {L26/P-765 Serum biomarkers for diagnosis of adolescent polycystic ovary syndrome: a systematic review and meta-analysis},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1092}
}
EUVIMED